

Amendments to the Specification:

Please replace the paragraph beginning at page 13, line 16, with the following amended paragraph:

(v) a method for modulating the inflammation, cell death, cell survival or other pathways in cells which are modulated directly or indirectly by B1, comprising treating said cells with an oligonucleotide sequence ~~encoding~~which is an antisense sequence for at least part of the DNA sequence encoding a B1 protein of the invention, said oligonucleotide sequence being capable of blocking the expression of the B1 protein.

Please replace the paragraph beginning at page 14, line 23, with the following amended paragraph:

Another embodiment of the above pharmaceutical composition is one for modulating the inflammation, cell death, cell survival or other pathways in cells which are modulated directly or indirectly by B1, comprising as active ingredient, an oligonucleotide sequence ~~encoding~~which is an anti-sense sequence of the B1 protein mRNA sequence.

Please replace the paragraph beginning at page 47, line 22, with the following amended paragraph:

As mentioned above, the present invention also relates to pharmaceutical compositions comprising recombinant animal virus vectors encoding the B1 proteins, which vector

Appln. No. 09/445,223
Amdt. dated October 7, 2003
Reply to Office action of May 7, 2003

also encodes a virus surface protein capable of binding specific target cell (e.g., cancer cells) surface proteins to direct the insertion of the B1 protein sequences into the cells. Further pharmaceutical compositions of the invention comprises as the active ingredient (a) an oligonucleotide sequence encoding which is an anti-sense sequence of the B1 protein sequence, or (b) drugs that block the B1 interaction with other proteins.